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Abstract
Purpose: To assess how the current practice of newborn screening (NBS) for
homocystinurias compares with published recommendations.
Methods: Twenty-two of 32 NBS programmes from 18 countries screened for at least
one form of homocystinuria. Centres provided pseudonymised NBS data from patients
with cystathionine beta-synthase deficiency (CBSD, n = 19), methionine adenosyltrans-
ferase I/III deficiency (MATI/IIID, n = 28), combined remethylation disorder (cRMD,
n = 56) and isolated remethylation disorder (iRMD), including methylenetetrahydrofolate
reductase deficiency (MTHFRD) (n = 8). Markers and decision limits were converted to
multiples of the median (MoM) to allow comparison between centres.
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Results: NBS programmes, algorithms and decision limits varied considerably. Only
nine centres used the recommended second-tier marker total homocysteine (tHcy). The
median decision limits of all centres were ≥ 2.35 for high and ≤ 0.44 MoM for low
methionine, ≥ 1.95 for high and ≤ 0.47 MoM for low methionine/phenylalanine,
≥ 2.54 for high propionylcarnitine and ≥ 2.78 MoM for propionylcarnitine/acetylcar-
nitine. These decision limits alone had a 100%, 100%, 86% and 84% sensitivity for the
detection of CBSD, MATI/IIID, iRMD and cRMD, respectively, but failed to detect
six individuals with cRMD. To enhance sensitivity and decrease second-tier testing
costs, we further adapted these decision limits using the data of 15 000 healthy
newborns.
Conclusions: Due to the favorable outcome of early treated patients, NBS for homo-
cystinurias is recommended. To improve NBS, decision limits should be revised con-
sidering the population median. Relevant markers should be combined; use of the
postanalytical tools offered by the CLIR project (Collaborative Laboratory Integrated
Reports, which considers, for example, birth weight and gestational age) is recom-
mended. tHcy and methylmalonic acid should be implemented as second-tier markers.
1 | INTRODUCTION
Homocystinurias are rare genetic diseases caused by defi-
cient activity of enzymes involved in the metabolism of sul-
fur amino acids or of the related B vitamins. Although these
diseases are aetiologically and clinically heterogeneous, they
share the biochemical feature of elevated concentrations of
homocyst(e)ine in blood and urine. This study focuses on
classical homocystinuria or cystathionine beta-synthase defi-
ciency (CBSD), the combined remethylation disorder
(cRMD), cblC, cblD-MMA-Hcy, cblF, cblJ, and the isolated
remethylation disorder (iRMD), cblD-Hcy, cblE, cblG, and
methylenetetrahydrofolate reductase (MTHFR) deficiency.
Although methionine adenosyltransferase I/III deficiency
(MATI/IIID) is generally not characterized by homocysti-
nuria, it was included in this study because its detection by
newborn screening (NBS) is closely related to NBS for
CBSD and discussed in this context.1
The clinical manifestation of untreated homocystinurias
depends on the affected gene and the severity of mutations.
Often, cognitive impairment, seizures, white matter and ocu-
lar abnormalities, connective tissues involvement and throm-
boembolism are presenting signs. Details on the clinical
features, diagnostic and therapeutic strategies, and efficacy
of treatment were recently reviewed.2,3 The evidence dis-
cussed in these and other publications4–12 indicates that
patients with homocystinurias may benefit from early treat-
ment. A small window of opportunity for efficient
intervention—especially in RMD—highlights the need for
timely diagnosis, preferably by NBS.
Ideally, NBS programmes should reliably detect patients
suffering from a well-characterized disorder, in which early
treatment is beneficial, using high quality, economically fea-
sible screening tests.13–15 In the past several decades, differ-
ent NBS strategies for the homocystinurias have been
developed. Several recent publications have proposed to
adopt two-tier screening strategies.2,16–20 These approaches
recommended to assess in a first step the primary markers:
(a) elevated methionine (Met) and/or methionine-to-
phenylalanine (Met/Phe) ratio for CBSD; (b) low Met and/or
Met/Phe levels for RMD; and (c) elevated propionylcarnitine
(C3), propionyl/acetylcarnitine (C3/C2) ratio and possibly
C3/Met or heptadecanoylcarnitine for cRMD2,16,21 from
dried blood spots (DBS). Subsequently, the second-tier
markers total homocysteine (tHcy) for all homocystinurias
and methylmalonic acid (MMA) for cRMD should be ana-
lyzed in the small number (approximately 1%) of DBS with
abnormal concentrations of primary markers.
The establishment of optimal decision thresholds is
among the most challenging tasks for NBS programmes.
Decision limits closer to the median of the marker in the
population of healthy newborns increase sensitivity but,
simultaneously, increase the false-positive rate, which deter-
mines the cost of second-tier testing. While decision limits
more distant from the population median reduce the false-
positive rate, they may fail to detect patients.
It has been suggested that NBS centres should pool data
and share experience on the NBS algorithms for homocysti-
nurias, as proposed by Gramer et al..16 However, the compa-
rability of data among different NBS centres is a generic
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problem of population screening programmes, due to for
example, different analytical platforms, times of sampling
and decision thresholds. The use of Z-scores or multiples of
the median (MoM) has been proposed to facilitate pooling
data across various screening programmes.14,22,23
This work was part of the EU-funded European Network
and Registry for Homocystinurias and Methylation Defects
(E-HOD; http://www.e-hod.org) project and investigates the
current practice of NBS for homocystinurias in 18 countries
involved in the E-HOD project. We analyzed the spectrum
of screened disorders, screening strategies and their con-
formity with recently published recommendations.2,16,18
Furthermore, this study evaluated the variation in decision
limits and examined whether the use of MoM-corrected
data could improve the performance of NBS for the
homocystinurias.
2 | METHODS
2.1 | Data acquisition
E-HOD partners were invited to answer a survey addressing
their regional practice of NBS for the homocystinurias with
the following key questions:
1. Are homocystinurias part of your NBS panel?
2. Which algorithms do you use to detect homocystinurias?
3. Does your programme use second-tier testing for tHcy?
4. What are the median values of Met, Met/Phe ratio, C3
and C3/C2 ratio markers in the population of healthy
newborns in your centre?
5. Which decision limits do you use to flag the result of
NBS as abnormal?
Pseudonymised data sets from 141 patients (from 23 cen-
tres) were extracted from the E-HOD registry; one additional
E-HOD centre contributed data sets from ten patients not yet
included into the registry (n = 151). Only patients younger
than 10 years of age at data entry were selected to facilitate
retrieval of data on NBS markers from local sources. Forty
patients had to be excluded from further analyses due to
missing data on the patient's marker at NBS, or medians of
the local newborn population or information on centre deci-
sion limits (n = 12 with CBSD, n = 10 with cRMD, n = 10
with iRMD), or due to complete absence of NBS data in
recently described very rare diseases (n = 5 with S-
adenosylhomocysteine hydrolase deficiency and n = 3 with
adenosine kinase deficiency), resulting in a final sample of
111 individuals. Four groups of patients were defined:
CBSD (n = 19), MATI/IIID (n = 28), cRMD (cblC, cblD,
cblJ) (n = 56) and iRMD (MTHFR, cblE, cblG) (n = 8).
For CBSD, no subgroup classification according to
pyridoxine responsiveness was attempted, as vitamin B6
response criteria from individual centres were ambiguous.
2.2 | Calculation of MoM-corrected decision
limits and marker values in patients
To allow the comparison of data across populations and cen-
tres using different screening platforms, we calculated MoM
of the Met, Met/Phe, C3 and C3/C2 decision limits reported
by the NBS centres by dividing the values of each marker
by its population median. The standardization of individual
NBS marker values of patients with homocystinurias to
MoM was performed accordingly.
2.3 | Performance of decision limits
To assess the performance of the highly dispersed decision
limits, we calculated the range and median decision limits
for each MoM-normalized marker. In a subset of patients
with complete data sets, we evaluated the sensitivity of the
extreme values and of the median of decision limits by cal-
culating the proportion of patients with homocystinurias that
would be detected by the respective decision limit. In addi-
tion, we analyzed the sensitivity of a combination of markers
and created respective two-dimensional plots.
2.4 | Modeling sensitivity, specificity and cost-
effectiveness in one NBS programme
For this analysis, data on markers in 15 000 healthy new-
borns from one NBS programme were combined with data
of the 111 patients reported in this study. For each of the four
targeted (groups of) disorders (CBSD, MATI/IIID, iRMD
and cRMD), we examined how the use of specific decision
limits would influence the sensitivity and specificity of the
combination of markers in the model population. Firstly, we
constructed two-dimensional grids for Met and Met/Phe, or
C3 and C3/C2 values for the combined pool of controls and
patients. Next, we computed the sensitivity and specificity of
two scenarios, that is, when both markers would be exceed-
ing decision limits (marked as “AND” test) or when at least
one of the two markers would be crossing the decision limits
(marked as “OR” test). To compare the sensitivity and speci-
ficity of these marker combinations, we constructed receiver
operating characteristic (ROC) curves. Finally, we used the
data set to model specificity as an important determinant of
either the false-positive rate or of the cost of second-tier test-
ing by constructing contour plots of the sensitivity of
markers with specificity fixed at 99% and above. The annual
cost savings vs expenditure of the number of second-tier
tHcy tests was calculated from the costs of tHcy analysis in
DBS (approximately €30.90 per analysis) according to the
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reimbursement rate (including instrument depreciation and
labour) published in the directive of the Ministry of Health
of the Czech Republic on the reimbursement of healthcare
procedures for 2017 (https://www.mzcr.cz/dokumenty/
vyhlaska-c/2016_13142_999_3.html).
2.5 | Statistical methods
Computations and model testing were performed in the statisti-
cal language and environment R (v.3.2.2), and SPSS and NCSS
statistical software, respectively. Comparison of NBS markers
between patients missed by NBS and those detected by NBS
was carried out using Statistica Cz, version 12 (StatSoft, Inc.,
Tulsa, OK, USA); the Mann-Whitney U-test with Benjamini-
Hochberg correction for multiple testing was employed and sig-
nificance of the false discovery rate was set at <0.05.
Data on the median values of markers stratified by covari-
ates were extracted using the productivity tool “Reference
Range by Covariate” on the CLIR website (https://clir.mayo.
edu) on April 23, 2018. Graphs were constructed using Excel.
3 | RESULTS
3.1 | NBS programmes for homocystinurias in
surveyed countries
Thirty-two centres from 16 European and two non-European
countries contributed data on their NBS panels operating in
2016. The number of primarily targeted disorders varied con-
siderably among countries as well as among regional pro-
grammes within countries. Twenty-one centres screened for
CBSD and 15 primarily targeted cblC disease. The Italian,
Czech and Spanish centres and Qatar (analyses for Qatar per-
formed by the NBS Centre Heidelberg, Germany until 2016)
also screened for iRMD (MTHFRD and/or isolated
cobalamin-related remethylation defects). MATI/IIID was a
primary target in Austrian, Italian and some Spanish centres.
Data from the 2011 survey in 16 European countries24 and the
present study cannot be easily compared due to the different
grouping of disorders and countries included; however, four
European countries initiated screening for CBSD and two for
cRMD as the primary target in at least one centre since 2011.24
3.2 | NBS algorithms
Detailed information on NBS algorithms was available for
19 centres reporting a variety of combinations and sequences
of the use of Met, Met/Phe, C3 and C3/C2 markers. tHcy
was used as a primary marker only in Qatar. Although recent
recommendations propose so, only 9 of 24 centres adopted a
two-tier strategy with tHcy as the second-tier marker. As an
example of the complexity and heterogeneity of algorithms
in different NBS programmes, Supplementary Figure 1 sum-
marizes the approaches targeting the cblC defect and
other cRMD.
3.3 | Decision limits for Met, Met/Phe, C3
and C3/C2
To test whether differences in decision limits among pro-
grammes are caused by different concentrations or ratios of
markers in the respective normal newborn populations, we
firstly compared the medians of each marker (see Figures 1
and 2). The distribution of markers in healthy newborns var-
ied substantially among centres. Medians for Met, Met/Phe,
C3 and C3/C2 were in the range 12.8-23 μmol/L, 0.22-0.51,
1.27-2.1 μmol/L and 0.057-0.18, respectively. It is, however,
of note that the dispersion of decision limits for Met,
Met/Phe, C3 and C3/C2 was even wider than the dispersion
of medians, indicating a substantial lack of consensus on
optimal thresholds to flag values as abnormal (Figures 1 and
2 and Supplementary Table 1).
FIGURE 1 Decision limits and marker values in patients with cystathionine beta-synthase deficiency (CBSD) and methionine
adenosyltransferase I/III deficiency (MATI/IIID)
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3.4 | Sensitivity of decision limits to detect
patients with homocystinurias
In the subset of patients with complete data sets, we evalu-
ated the sensitivity of decision limits.
3.4.1 | Performance of centres' decision limits
The proportion of patients with homocystinurias that would
be detected according to the decision limits of respective
centres varied considerably and clearly showed that some
programmes use decision limits with unsatisfactory sensitiv-
ity (Supplementary Table 1).
Since there is no consensus on the optimal decision
thresholds, we examined in the next step the sensitivity of
the medians of decision limits of all programmes (as the
possible best proxy of consensual values), as well as the
sensitivity of combinations of markers. These medians of
MoM-normalized decision limits of all centres are labeled
as “suggested cut-offs” in the following paragraphs
(Table 1).
3.4.2 | Performance of median decision limits
of high Met and Met/Phe to detect CBSD and
MATI/IIID
The suggested cut-offs for high Met (≥ 2.35 MoM) or
high Met/Phe (≥ 1.95 MoM) detected all 17 patients with
CBSD and all 28 patients with MATI/IIID in this study.
Congruently, the AND/OR combination of these markers
detected all patients (Supplementary Tables 1 and 2 and
Figure 1).
3.4.3 | Performance of median decision limits
of low Met and Met/Phe to detect iRMD
The study cohort contained data on Met from eight and
Met/Phe from seven patients with iRMD. The suggested cut-
off for low Met (≤ 0.44 MoM) detected only three of eight
patients; low Met/Phe (≤ 0.47 MoM) would detect six of
seven patients. The combination of low Met AND/OR low
Met/Phe would detect six of seven patients (Supplementary
Tables 1, 2 and 3 and Figure 2).
FIGURE 2 Decision limits and marker values in patients with isolated remethylation disorder (iRMD) and combined remethylation
disorder (cRMD)
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TABLE 1 Newborn screening (NBS) panels for homocystinurias in 2016 [data provided by European Network and Registry for
Homocystinurias and Methylation Defects (E-HOD) partners]
Countries, reporting centres CBS
cblC
(cblD)
MTHFR
deficiency cblE/cblG MATI/III
tHcy,
second tier
Interval from birth to
blood sampling (hours)
Approximate
no. screened/year
Austria1,a,b (Vienna) X X – – X N 36–72 90,000
Czech Republic2
Prague X (X) X (X) (X) Y 48–72 80,000
Hungary2,a,b
Szeged X – – – X N 48–72 48,000
Ireland1,a (Dublin) X – – – – N 72–120 72,000
Italy2
Genoa X X X X X N 48–72 10,000
Rome X X X X X Y 48–72 25,000
Florence X X X X X Y 48–72 38,000
Cagliari Sardinia X X – – – Y 48–72 12,000
Portugal1,a,b (Porto) X X – – X N 48–72 85,000
Qatar1 (performed in
Heidelberg, Germany until
2016)
X X X X – Y* < 48 25,000
Spain2,a,b
Barcelona X X X X – Y 48–72 71,000
Malaga X X – – X N 48–72 40,000
Sevilla X X – X X N 48–72 53,834
Madrid – X – X – N 48–72 75,000
Albacete – – – – – N 48–72 9,723
Las Palmas – – – – – N < 48 9,500
Palma de Mallorca X X – – X N 48–72 40,000
Valladolid – – – – – N 48–72 17,523
S. de Compostela X X X – X Y 48–72 19,756
Zaragoza X X X (X) (X) N 48–72 14,500
Murcia and Melilla X – – – – N < 48 17,950
Bilbao X – – – – N < 48 19,749
Sweden1 (Stockholm) X (X) – – (X) Y 48–96 115,000
USA2
Colorado and Wyoming
(Denver)
X X – – – < 48 72,000
UK2
Wales (Cardiff) X – – – – Y > 72 36,500
– = not primarily targeted; X = primary target; (X) = secondary target (may be detected, although not targeted); Y = yes; N = no; *tHcy used as the primary marker
in the Qatar NBS screening programme only.
1Single centre per country.
2More than one centre per country.
Countries with NBS for aCBS or bmethylmalonic acidaemia, including Cbl A, B, C, D defects, in place in a European survey of 2011.24
No No NBS for these disorders in: Belgium2,b (Brussels, Flemish part); Switzerland1 (Zurich); Germany2 (Heidelberg); Slovenia1 (Ljubljana); Croatia1 (Zagreb);
Denmark1,b (Copenhagen); France2 (Paris).
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3.4.4 | Performance of median decision limits
of low Met and Met/Phe, and high C3 and
C3/C2 to detect cRMD
The group of patients with cRMD with any information on
decision limits consisted of 47 subjects, of which six had
been missed by their original NBS programme (another
cRMD patient missed by NBS was excluded from these ana-
lyses due to missing information on decision limits). Data
sets (all four markers) were not complete in all patients.
The sensitivity of the suggested cut-offs for low Met (≤
0.44 MoM) and low Met/Phe (≤ 0.47 MoM) was poor,
detecting only 22 and 28 of 47 patients, respectively. In con-
trast, the suggested cut-offs for high C3 (≥ 2.54 MoM) and
C3/C2 (≥ 2.78 MoM) performed better, detecting 41 of
47 and 33 of 45 patients, respectively. The AND/OR combi-
nation of all four markers yielded slightly better results. At
least one marker was outside the reference range in 43 cases.
In summary, the combination of all four markers detected
more patients with cRMD compared to the use of only single
markers, but their performance was not sufficient to detect
all patients.
In order to shed more light on the subgroup of the
patients missed by their local NBS programmes, we con-
ducted a detailed analysis of the NBS markers obtained at
the time of screening. The NBS markers for cblC and cRMD
in general are high C3 and C3/C2, or low methionine and
Met/Phe. Compared to patients with cblC disease detected
by regional NBS programmes (data available for n = 28),
patients undetected by NBS (data available for n = 6) exhib-
ited significantly higher median Met (1.7 times), MoM Met
(2 times), Met/Phe (1.9 times) and MOM Met/Phe
(2.4-times), as well as significantly lower C3 (41%), MoM
C3 (45%), C3/C2 (52%) and MOM C3/C2 (53%). These
analyses demonstrate that cblC patients (or cRMD patients
in general) with milder biochemical phenotype at the time of
blood sampling may be missed by NBS even if consensual
decision limits would be used (Supplementary Table 4).
3.5 | Sensitivity, specificity and cost-
effectiveness in a model NBS programme using
median decision limits of all NBS programmes
The analysis of specificity and sensitivity requires not only
data on marker values in patients, but also data on marker
distributions in the population of healthy newborns. As an
example of how data from this study may be used for opti-
mizing NBS programmes, we modeled these markers using
data on Met and Met/Phe in 15 000 newborns from one
selected NBS programme.
The left panels in Figure 3 show the ROC curves for dif-
ferent markers and truth-functional operators (ie, the AND
combination of two markers or the OR combination of two
markers). The area under the ROC curve is over 0.99 in
CBSD using either high Met AND high Met/Phe or high
Met OR high Met/Phe. For cRMD, the area under the ROC
curve was substantially higher for marker combinations
employing high C3 AND/OR high C3/C2 (0.97 and 0.98,
respectively) compared to the combination low Met
AND/OR low Met/Phe (0.84 and 0.87, respectively).
The middle and right panels of Figure 3 show nomo-
grams of specificity at different fixed sensitivities and nomo-
grams of sensitivity at a fixed specificity of 0.99. In this
study, the nomograms were used to optimize the decision
limits of a single NBS programme for homocystinurias.
Lowering of the present decision limits for high Met and
high Met/Phe from 2.7 to 2.56 and from 2.27 to 2.08,
respectively, increased the sensitivity for detecting CBSD
from 0.94 to 1.0; the number of second-tier tests increased
by only 0.03%, with a cost increase from €4942 to €5766
per year. For iRMD, an increase of the decision limits for
low Met and low Met/Phe from 0.50 to 0.53 MoM and from
0.55 to 0.60 MoM, respectively, maintained the same sensi-
tivity of 0.88; this modification decreased substantially the
number of second-tier tests of tHcy from 1.8 to 0.9% and the
costs from €39 867 to €16 639 per year. In this analysis, the
modified approach for the model-tested NBS programme
yielded a sensitivity of 1 for CBSD and 0.88 for iRMD, with
less demand for second-tier tHcy testing, leading to savings
of €22 404 per year.
4 | DISCUSSION
The long-term evidence on favorable clinical outcome in
early treated patients strongly indicates that CBSD is a good
candidate for NBS.2,3,16,18 NBS for RMD should at least be
considered.2,4,8–10,25 MTHFR deficiency seems to be partic-
ularly responsive to early betaine treatment5 and the majority
of cobalamin-related RMD have a better clinical outcome
with less mortality or severe organ complications when trea-
ted early. Brain and eye disease in RMD (especially in the
cblC defect), however, may progress despite treatment. The
recommendations on MATI/IIID as a target condition are
controversial, mostly due to the detection of large numbers
of heterozygotes.2
This study involving 18 countries shows that NBS prac-
tice is not concordant with these recommendations and,
despite some evolution since 2011,24 NBS for the homocys-
tinurias is not widely established.
The decision on disorders to be included into NBS pro-
grammes is only partly evidence based. The final pro-
gramme setup is a political decision of states, regions and
institutions, and this explains the heterogeneity among dif-
ferent regions and countries. In the USA, the Advisory Com-
mittee on Heritable Disorders in Newborns and Children
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(https://www.hrsa.gov/advisorycommittees/mchbadvisory/he
ritabledisorders/recommendedpanel) recommended screen-
ing for CBSD as a primary target, and RMD and MATI/IIID
as secondary conditions. In the EU, the absence of harmo-
nized recommendations is reflected in the wide range from
none to seven forms of homocystinuria targeted in different
European NBS programmes. Interestingly, there is consider-
able variation in the types of homocystinuria included in
NBS panels, even between regions within one country,
reflecting different decision-making routes.
This study also showed a large variability in decision
limits between individual programmes and demonstrated
that some programmes use decision limits with suboptimal
sensitivity. Only a small proportion of programmes use
second-tier strategies that would allow the implementation
of decision limits with higher sensitivity.
There are several reasons for the differences in decision
limits between centres. Most probably, the different perfor-
mance, of the various analytical programmes in place add to
the heterogeneity we observe. This effect is demonstrated by
FIGURE 3 Model of the sensitivity and specificity of markers for detecting CBSD and cRMD
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the Centers for Disease Control and Prevention (CDC) New-
born Screening Quality Assurance Program. Data from the
CDC on Set 2 July-October 201626 show that, between
seven different types of analytical platforms, the mean Met
concentrations in a single DBS batch varied between 17.6
and 24.1 μmol/L.
The variable age at sampling may be a factor, given the
physiological changes in marker concentrations during the
first days of life. In the Collaborative Laboratory Integrated
Reports (CLIR; http://clir.mayo.edu), considerable changes
of marker values within the interval of sampling after birth
are apparent for Met (median 23 μmol/L at 24 hours and
20.1 μmol/L at 48 hours), Met/Phe (median 0.41 at 24 hours
and 0.39 at 60 hours) and C3/C2 (median 0.075 at 48 hours
and 0.081 at 60 hours). For details, see Supplementary
Figure 3.
In term-born (between 37 and 41 weeks of gestation)
newborns with normal weight (2500-4200 g), the influence
of other covariates appears less pronounced compared to the
influence of sampling time. Sex seems to be only associated
with the C3/C2 ratio (approximately 0.003 higher in
females). Birth weight and gestational age are negatively
correlated with Met and Met/Phe (eg, a decrease of approxi-
mately 0.02 for Met/Phe from the highest gestational age or
weight to the lowest gestational age or weight). Furthermore,
birth weight and gestational age are positively correlated
with C3 and C3/C2 (eg, C3/C2 increases by approximately
0.08 and 0.09 from the highest gestational age or weight to
the lowest gestational age or weight, respectively).
Newborns with lower or higher birth weight or born ear-
ly/late, however, exhibit larger variability of marker values,
clearly indicating the necessity of using weight- and/or ges-
tational age-adjusted marker values (http://clir.mayo.edu27).
The effect of different platforms and sampling times may
be reduced by using MoM. Nevertheless, in this study, the
use of MoM-corrected values did not decrease the huge vari-
ability of decision limits among centres. The lack of concor-
dance may be explained by the use of different metrics (eg,
different percentiles of the reference population used as cut-
offs), various degrees of acceptance of false positivity or dif-
ferent follow-up procedures in individual programmes.
Second-tier testing allows more sensitive decision limits
to be adopted without causing a massive increase in false-
positive results. This is important as recalls lead to psycho-
logical stress for families and increased costs.16,28 Gramer
et al.16 have proposed an algorithm to detect CBSD and
RMD with tHcy as a second-tier test in all newborns with
abnormalities in either Met (lower cut-off only) or Met/Phe
(lower and upper cut-offs) or elevated C3 or C3/C2. This
approach was tested in a single centre and did not only iden-
tify patients from the local population but also patients docu-
mented in the Region 4 Collaborative Project.16 The authors
show that second-tier measurement of tHcy allows adjusting
the decision limits of the primary markers towards the
median, which results in a smaller proportion of undetected
patients. These and similar recommendations to use tHcy
and/or MMA as second-tier markers2 have not yet been
widely adopted in NBS practice, as demonstrated by our
study. Consequently, many NBS programmes for homocys-
tinurias have unnecessarily large numbers of false-positive
results and miss the opportunity to establish more sensitive
decision limits. There are currently ongoing pilot studies
evaluating the use of second-tier strategies for homocysti-
nurias and RMD, which may lead to wider application of
such strategies in the future.29,30
A most promising approach to increase both the sensitiv-
ity and specificity of NBS and to become increasingly inde-
pendent from single-parameter decision limits is the use of
postanalytical tools as offered by the CLIR project. These
tools integrate information on larger sets of markers and cor-
rect for covariates using comprehensive statistical proce-
dures. Unfortunately, data on the majority of the parameters
used by the tools were fragmentary or not available at all in
our sample, owing to the retrospective design of the E-HOD
registry project.
This study has several limitations. It is not entirely repre-
sentative as it exclusively includes centres participating in
the E-HOD project, who may have a particular interest in
homocystinurias. In addition, the retrospective nature of this
study did not permit collecting uniform, complete data sets
for all cases. It is also important to note that the favorable
cost-effectiveness analysis was estimated from a single pro-
gramme, and may not be universally applicable.
With the exception of seven cblC/cblD patients missed
by NBS, all data on marker values come from patients
detected by NBS. Consequently, marker values from
patients with milder forms of disease are probably underrep-
resented in the data set, which, in turn, probably leads to a
biased evaluation of decision thresholds. Unfortunately,
false-negative cases are not easily detectable and the retro-
spective analyses of stored DBS from patients with milder or
late-onset forms of homocystinurias are hampered by the
instability of some markers, ethical concerns or the early
destruction of DBS according to local or national policies.
5 | CONCLUSIONS
This study demonstrates that many newborn screening
(NBS) programmes have not yet implemented the recent rec-
ommendations on screening for the homocystinurias. Due to
the favorable outcome of early treated patients, we recom-
mend the implementation of NBS for homocystinurias in
national and regional programmes. To improve the
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performance of NBS programmes, we recommend a four-
step strategy:
1. Thorough revision of local decision limits with reference
to the median of the local reference population.
2. Combination of relevant markers, as demonstrated in
this study.
3. Use of the centre-adjusted postanalytical tools offered
by the Collaborative Laboratory Integrated Reports
(CLIR) project, which, in addition, considers covariates
such as birth weight, gestational age and sampling time.
4. Implementation of total homocysteine (tHcy) and
methylmalonic acid (MMA) as second-tier markers to
allow for more sensitive decision limits, increased speci-
ficity and lower costs.
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